Nakashio S, Iwasawa H, Dun F Y, Kanemitsu K, Shimada J
Institute of Medical Science, St. Marianna University, Kawasaki, Japan.
Drugs Exp Clin Res. 1995;21(1):7-16.
Antimicrobial activity of everninomicin (SCH) 27899) in comparison with two glycopeptides (vancomycin, teicoplanin) and six beta-lactam agents was evaluated against recent clinical isolates of Gram-positive bacteria. Everninomicin showed the highest activity against the species tested and MICs90% of everninomicin against Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium and Clostridium difficile were 0.1, 0.1, 0.2, 0.39, 0.1 microgram/ml, respectively. MICs90% of everninomicin against methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE) were 0.78 microgram/ml. Laboratory induced resistance to everninomicin in strains of S. aureus and E. faecalis occurred in a stepwise manner and at a very slow rate. Post-antibiotic effect against strains of S. aureus and E. faecalis were 1.8 and 2.6 h, respectively, and a little longer than that of vancomycin. Adherence to glass surface of an MRSA strain was strongly repressed by the addition of sub MIC of everninomicin in combination with fosfomycin.
将埃维霉素（SCH 27899）与两种糖肽类抗生素（万古霉素、替考拉宁）及六种β-内酰胺类药物的抗菌活性进行比较，评估其对近期革兰氏阳性菌临床分离株的抗菌效果。埃维霉素对所测试的菌种显示出最高活性，其对肺炎链球菌、化脓性链球菌、粪肠球菌、屎肠球菌和艰难梭菌的90%最小抑菌浓度（MICs90%）分别为0.1、0.1、0.2、0.39、0.1微克/毫升。埃维霉素对耐甲氧西林金黄色葡萄球菌（MRSA）和表皮葡萄球菌（MRSE）的MICs90%为0.78微克/毫升。金黄色葡萄球菌和粪肠球菌菌株对埃维霉素的实验室诱导耐药以逐步方式发生，且速率非常缓慢。对金黄色葡萄球菌和粪肠球菌菌株的抗生素后效应分别为1.8小时和2.6小时，略长于万古霉素。在耐甲氧西林金黄色葡萄球菌菌株中，加入低于最小抑菌浓度的埃维霉素与磷霉素联合使用时，对玻璃表面的黏附受到强烈抑制。
